1. Home
  2. ATNI vs BNR Comparison

ATNI vs BNR Comparison

Compare ATNI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATN International Inc.

ATNI

ATN International Inc.

HOLD

Current Price

$20.98

Market Cap

226.4M

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$15.72

Market Cap

233.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNI
BNR
Founded
1987
2014
Country
United States
China
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical Specialities
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.4M
233.7M
IPO Year
1991
2020

Fundamental Metrics

Financial Performance
Metric
ATNI
BNR
Price
$20.98
$15.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
55.8K
63.8K
Earning Date
11-05-2025
11-20-2025
Dividend Yield
5.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$724,308,000.00
$75,749,382.00
Revenue This Year
$1.77
$136.32
Revenue Next Year
$2.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.56
52 Week Low
$13.76
$2.18
52 Week High
$23.60
$23.59

Technical Indicators

Market Signals
Indicator
ATNI
BNR
Relative Strength Index (RSI) 64.97 48.27
Support Level $21.05 $17.66
Resistance Level $21.99 $23.59
Average True Range (ATR) 0.79 2.69
MACD -0.09 -0.30
Stochastic Oscillator 59.41 17.85

Price Performance

Historical Comparison
ATNI
BNR

About ATNI ATN International Inc.

ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: